[Helicobacter pylori and gastroduodenal ulcers]

Area of Science:

• Gastroenterology
• Microbiology
• Internal Medicine

Background:

• Helicobacter pylori (H.P.) is a significant pathogen implicated in various gastroduodenal diseases.
• Understanding H.P. prevalence and its impact on ulcer healing and inflammation is crucial for effective management.

Purpose of the Study:

• To investigate the prevalence of H.P. infection in patients with gastroduodenal diseases.
• To assess the efficacy of short-term antimicrobial therapy and its long-term impact on H.P. recurrence and gastric inflammation.

Main Methods:

• Prevalence of H.P. infection determined in gastric and duodenal ulcer patients.
• Assessment of H.P. presence during ulcer healing and one year post-treatment.
• Evaluation of short-term antimicrobial therapy efficacy (cefixim, ofloxacin, bismuth subnitrate).
• Histological analysis of antral mucosa inflammation in H.P. positive and negative patients.

Main Results:

• H.P. positivity rates were 67.6% in gastric ulcer and 82.2% in duodenal ulcer patients.
• H.P. was frequently detected during ulcer healing and recurred in a significant number of patients one year after treatment.
• Antimicrobial therapy achieved a 50% success rate in H.P. positive patients.
• Histological inflammation was more pronounced in H.P. positive patients, and H.P. eradication improved this inflammation.

Conclusions:

• H.P. infection is highly prevalent in gastroduodenal ulcers and frequently persists despite short-term therapy.
• Eradication of H.P. positively impacts gastric mucosal inflammation, regardless of other medications used.